Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Colorectal Neoplasms 3Carcinoma, Renal Cell 2Triple Negative Breast Neoplasms 1Solid Tumors 1Rectal Neoplasms 1Myelodysplastic Syndromes 1Melanoma 1Leukemia, Myelomonocytic, Chronic 1Hereditary Sensory and Autonomic Neuropathies 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Azacitidine 26venetoclax 12Peripheral Blood Stem Cell Transplantation 12fludarabine phosphate 10Mycophenolic Acid 9Whole-Body Irradiation 8Cyclosporine 8Cytarabine 7Cyclophosphamide 6Filgrastim 5Decitabine 5Busulfan 5Methotrexate 4fludarabine 3aldesleukin 3Tacrolimus 3Granulocyte Colony-Stimulating Factor 3Flow Cytometry 3Cytogenetic Analysis 3Cyclosporins 3Biopsy 3tipifarnib 2tagraxofusp 2ruxolitinib 2quizartinib 2eprenetapopt 2axatilimab 2X-Rays 2Transplantation 2Topotecan 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Leukemia, Myelomonocytic, Chronic × CB-839 × Clear all
NCT03047993 2024-05-14

Glutaminase Inhibitor CB-839 and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndrome

M.D. Anderson Cancer Center

Phase 1/2 Completed
28 enrolled 8 charts
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡